Bristol Myers Squibb Company $BMY Stake Increased by Waverly Advisors LLC

Waverly Advisors LLC increased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 306.6% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 349,560 shares of the biopharmaceutical company’s stock after purchasing an additional 263,590 shares during the quarter. Waverly Advisors LLC’s holdings in Bristol Myers Squibb were worth $20,142,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of BMY. California State Teachers Retirement System boosted its position in Bristol Myers Squibb by 5,484.7% during the 2nd quarter. California State Teachers Retirement System now owns 185,255,963 shares of the biopharmaceutical company’s stock worth $10,674,449,000 after acquiring an additional 181,938,762 shares during the period. Norges Bank acquired a new position in shares of Bristol Myers Squibb in the 4th quarter valued at about $1,947,272,000. Primecap Management Co. CA purchased a new stake in shares of Bristol Myers Squibb in the second quarter worth approximately $1,436,115,000. Legal & General Group Plc acquired a new stake in shares of Bristol Myers Squibb during the second quarter worth approximately $980,862,000. Finally, AQR Capital Management LLC grew its position in Bristol Myers Squibb by 172.6% during the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock valued at $1,391,485,000 after purchasing an additional 16,332,924 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Stock Performance

BMY stock opened at $64.63 on Wednesday. The firm has a 50 day moving average of $63.23 and a two-hundred day moving average of $60.00. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $68.64. The company has a market capitalization of $132.02 billion, a price-to-earnings ratio of 14.24, a P/E/G ratio of 0.32 and a beta of 0.23. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter last year, the firm earned $1.46 EPS. Bristol Myers Squibb’s revenue for the quarter was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities analysts anticipate that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were given a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.9%. Bristol Myers Squibb’s payout ratio is currently 55.51%.

Insider Buying and Selling at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.05% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on BMY shares. Citigroup reiterated a “neutral” rating and issued a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. Cantor Fitzgerald restated a “neutral” rating and set a $59.00 price target (up from $54.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. UBS Group downgraded shares of Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 5th. BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. Finally, Bank of America lowered their target price on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research note on Friday, July 10th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Moderate Buy” and an average target price of $66.06.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.